What is the 59-gene ACMG list, and why is it debated in reporting?

Prepare for the Clinical Genetics Test. Utilize flashcards and multiple-choice questions, each with hints and explanations. Achieve success on your exam!

The 59-gene ACMG list identifies genes in which a pathogenic variant has established medical actionability, meaning there are proven steps—such as specific surveillance, risk-reducing strategies, or treatments—that can reduce illness or prevent mortality. Clinicians are encouraged to report such variants even if they are not the primary target of testing, because knowing them can directly impact patient care.

This list is debated because reporting actionable findings involves balancing benefits with potential harms. Actionability can vary by age, penetrance, and individual context, so what is clearly beneficial for one person might not be for another. There are ethical and practical concerns about patient autonomy and consent (should patients be asked whether they want to know about incidental findings?), possible anxiety or unnecessary procedures, and resource use. Additionally, there is ongoing discussion about which genes truly meet the bar for actionability and how the list should be updated as evidence evolves.